IP Library Granted Patent US 10,703,743
Granted Patent B2
US 10,703,743 · App. 16/037,678 · Granted Jul 7, 2020

Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus

Inventors: David Spiegel (New Haven, CT); Christopher Parker (Medina, OH)
Assignee: YALE UNIVERSITY
C07D405/14A61K9/0014A61K31/496A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,703,743
App. No.
16/037,678
Granted
Jul 7, 2020
Kind
B2
Abstract

The present invention is directed to new bifunctional compounds and methods for treating HIV infections. The bifunctional small molecules, generally referred to as ARM-HI's, function through orthogonal pathways, by inhibiting the gp120-CD4 interaction, and by recruiting anti-DNP antibodies to gp120-expressing cells, thereby preventing cell infection and spread of HIV. It has been shown that ARM-HI's bind to gp120 and gp-120 expressing cells competitively with CD4, thereby decreasing viral infectivity as shown by an MT-2 cell assay, the binding leading to formation of a ternary complex by recruiting anti-DNP antibodies to bind thereto, the antibodies present in the ternary complex promoting the complement-dependent destruction of the gp120-expressing cells. Compounds and methods are described herein.

Claims (20)

1. A method of synthesizing a compound according to the chemical structure 16:

where n and n′ are each independently an integer from 1 to 6, or a pharmaceutically acceptable salt thereof,

comprising reacting compound 10

with compound 4

in the presence of tetrakis(triphenylphosphine)palladium (Pd(PPh 3 ) 4 in dimethylformamide/water to produce compound 11 according to the chemical structure:

which is then reacted with N-(9-Fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSU) to produce compound 12

where Fmoc is a fluorenylmethoxycarbonyloxy group and Boc is a tertiarybuyloxycarbonyl group;

Compound 12 is then deprotected with trifluoroacetic acid to remove the Boc group to produce compound 13

or its triflouoroacetate salt, which is reacted with compound 2

to produce compound 14

which is deprotected to remove the Fmoc group to produce compound 15

compound 15 is then reacted with alkyne compound 8

where DNP is a dinitrophenyl group, in the presence of copper sulfate (CuSO 4 ) and ascorbate to produce compound 16 or a pharmaceutically acceptable salt thereof.

2. A compound according to the chemical structure:

where n and n′ are each independently an integer from 1-6, or a pharmaceutically acceptable salt thereof.

3. A compound of claim 2 according to the chemical structure:

where n is an integer from 1 to 6, or

a pharmaceutically acceptable salt thereof.

4. A compound of claim 2 according to the chemical structure:

where n and n′ are each independently an integer from 1-6, or a pharmaceutically acceptable salt thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 6, 2021
From: YALE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 054907/0833 →
Continuity (5)
Division 15379969 · Dec 15, 2016
Division 13988251
Provisional Application 61414977 · Nov 18, 2010
Provisional Application 61522518 · Aug 11, 2011
Related Publication 20190002447A1 · Jan 3, 2019